COMPANY

SynDevRx

Keywords: oncology cancer HR+/HER2-negative Breast Cancer Metastatic Breast Cancer Metastasis Evexomostat SDX-7320

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Aug 26, 2022 Trial start Phase 1/Phase 2: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer source ↗
2016-02 Trial start Phase 1: A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors source ↗

2026-12 (ESTIMATED) · Phase 1/Phase 2 · Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer · NCT05455619

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05455619	Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	Phase 1/Phase 2	Recruiting	Aug 26, 2022	2026-12 (estimated)
NCT02743637	A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors	Phase 1	Completed	2016-02	Dec 16, 2019 (actual)